(XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer

被引：0
|
作者：
Alu, M. [1 ]
Laudani, A. [1 ]
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Savio, G. [1 ]
Pepe, A. [1 ]
Arcuri, C. [1 ]
Cusimano, M. R. [1 ]
Calabria, C. [1 ]
Agostara, B. [1 ]
机构：
[1] Osped Oncol Maurizio Ascoli, Palermo, Italy
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71049-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3546
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [42] Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases
    Mahfouf, H.
    Djeddi, H.
    Belhadef, S.
    Bouzid, K.
    Bentabak, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [43] Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
    Zhao, G.
    Gao, P.
    Yang, K. H.
    Tian, J. H.
    Ma, B.
    COLORECTAL DISEASE, 2010, 12 (07) : 615 - 623
  • [44] First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis.
    Hwang, In Gyu
    Lee, Hyo Rak
    Lee, Hui Young
    Ji, Jun Ho
    Kang, Jung Hun
    Lee, Soon Il
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Se Hoon
    Kang, Won Ki
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX plus bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis
    Peria, F. M.
    Ungari, A. Q.
    Dos Santos, F. N.
    Lins-Almeida, T.
    Nunes, A. A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK).
    Borner, M.
    Mingrone, W.
    Koeberle, D.
    Von Moos, R.
    Rauch, D.
    Saletti, P.
    Herrmann, R.
    Dietrich, D.
    Lanz, D.
    Roth, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [47] Results of the use of oxaliplatin and capecitabine plus cetuximab as first-line therapy in the treatment of patients with metastatic colorectal cancer:: First analyses
    Barroso, S.
    Sanches, E.
    Marques, Ferreira J.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sottomayor, C.
    Espirito, Santo J.
    San-bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 74 - 75
  • [48] RESULTS OF THE USE OF OXALIPLATIN AND CAPECITABINE PLUS CETUXIMAB AS FIRST-LINE THERAPY IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER: FIRST ANALYSES
    Barroso, S.
    Sanches, E.
    Ferreira, J. M.
    Passos, M.
    Sa, A.
    Nabico, R.
    Sotto-Mayor, C.
    Santo, J. Espirito
    San-Bento, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [49] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [50] Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
    Luo, H. Y.
    Li, Y. H.
    Wang, W.
    Wang, Z. Q.
    Yuan, X.
    Ma, D.
    Wang, F. H.
    Zhang, D. S.
    Lin, D. R.
    Lin, Y. C.
    Jia, J.
    Hu, X. H.
    Peng, J. W.
    Xu, R. H.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1074 - 1081
12345